BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 14685796)

  • 1. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
    Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
    Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
    Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
    J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
    Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
    Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
    Gupta NP; Sharma N; Kumar R
    Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
    Mansoor I; Calam RR; Al-Khafaji B
    Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voided urinary cytology in bladder cancer: is it time to review the indications?
    Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N
    Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
    Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer.
    Landman J; Chang Y; Kavaler E; Droller MJ; Liu BC
    Urology; 1998 Sep; 52(3):398-402. PubMed ID: 9730450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
    Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS
    J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
    Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
    J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer.
    Lahme S; Bichler KH; Feil G; Zumbrägel A; Götz T
    Adv Exp Med Biol; 2003; 539(Pt A):111-9. PubMed ID: 15088900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor markers for bladder cancer: up-to-date study by the Kiel Tumor Bank].
    Hautmann S; Eggers J; Meyhoff H; Melchior D; Munk A; Hamann M; Naumann M; Braun PM; Jünemann KP
    Urologe A; 2007 Nov; 46(11):1508-13. PubMed ID: 17932643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.